Manifaxine (GW-320,659) is a drug developed by GlaxoSmithKline through structural modification of radafaxine, the active metabolite of bupropion. It acts as a norepinephrine-dopamine reuptake inhibitor (NDRI). It was researched for treatment of ADHD and obesity and was shown to be safe, reasonably effective and well tolerated for both applications, but no results have been reported following these initial trials and its current status is unclear.





This page contains text from Wikipedia, the Free Encyclopedia - http://en.wikipedia.org/wiki/Manifaxine

This article is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License, which means that you can copy and modify it as long as the entire work (including additions) remains under this license.









×